Brokerages Expect Qiagen N.V. (QGEN) Will Announce Quarterly Sales of $392.98 Million

Equities analysts expect that Qiagen N.V. (NASDAQ:QGEN) will announce sales of $392.98 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Qiagen’s earnings, with the lowest sales estimate coming in at $389.96 million and the highest estimate coming in at $396.00 million. Qiagen posted sales of $366.50 million during the same quarter last year, which would indicate a positive year over year growth rate of 7.2%. The business is scheduled to issue its next earnings report on Wednesday, February 7th.

According to Zacks, analysts expect that Qiagen will report full-year sales of $392.98 million for the current fiscal year, with estimates ranging from $1.40 billion to $1.43 billion. For the next financial year, analysts forecast that the firm will post sales of $1.51 billion per share, with estimates ranging from $1.50 billion to $1.53 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Qiagen.

Qiagen (NASDAQ:QGEN) last announced its earnings results on Monday, November 6th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.32. The business had revenue of $364.00 million for the quarter, compared to analyst estimates of $363.42 million. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the firm posted $0.29 earnings per share.

Several brokerages recently issued reports on QGEN. Zacks Investment Research upgraded shares of Qiagen from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a research report on Tuesday, October 10th. Cowen reiterated a “hold” rating and set a $33.00 price objective on shares of Qiagen in a report on Friday, November 3rd. Commerzbank reiterated a “buy” rating on shares of Qiagen in a research note on Tuesday, November 7th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Qiagen in a research note on Tuesday, November 7th. Finally, Deutsche Bank reissued a “buy” rating on shares of Qiagen in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $34.06.

A number of hedge funds have recently added to or reduced their stakes in the business. Atlanta Capital Management Co. L L C increased its position in Qiagen by 210.1% during the third quarter. Atlanta Capital Management Co. L L C now owns 1,314,274 shares of the company’s stock worth $41,400,000 after purchasing an additional 890,454 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new position in Qiagen during the second quarter valued at about $26,408,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Qiagen in the 2nd quarter valued at $18,234,000. WINTON GROUP Ltd acquired a new stake in shares of Qiagen during the 2nd quarter worth approximately $15,088,000. Finally, Vanguard Group Inc. grew its stake in shares of Qiagen by 7.0% during the second quarter. Vanguard Group Inc. now owns 6,053,863 shares of the company’s stock worth $202,986,000 after purchasing an additional 394,201 shares during the period. Institutional investors and hedge funds own 62.37% of the company’s stock.

Shares of Qiagen (QGEN) opened at $30.84 on Thursday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.78 and a current ratio of 5.33. Qiagen has a 12-month low of $27.51 and a 12-month high of $36.34. The stock has a market capitalization of $7,110.00, a P/E ratio of 25.40, a P/E/G ratio of 1.91 and a beta of 1.10.

ILLEGAL ACTIVITY WARNING: This news story was reported by Week Herald and is the property of of Week Herald. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Get a free copy of the Zacks research report on Qiagen (QGEN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with's FREE daily email newsletter.

Leave a Reply